Clinical Trials Logo

Clinical Trial Summary

This pilot study will assess the ability of daily consumption of two servings of California strawberries to alter gut microbiome composition, leading to increased bile secretion and decreased plasma cholesterol in a free-living population.


Clinical Trial Description

This will be a randomized, double-blinded, placebo controlled, parallel design. Thirty subjects will be randomized to consume two servings of standardized freeze-dried strawberry powder (2 x 13g) daily or placebo for 4 weeks, followed by 2 weeks of follow up with beige diet only to observe whether the effect can be sustained for 2 weeks. Blood will be collected at baseline (week 0), weeks 4 and week 6 after strawberry consumption. On the day prior to the study visits participants will collect a stool and a 24-hr urine sample and bring to the lab. In addition, body weight and composition will be determined and questionnaires and 3-day food record will be completed. Twenty-four hour urine content of pelargonidin glucuronide will be measured for compliance. Plasma and fecal cholesterol and bile acids will be determined at baseline (week 0) and weeks 4 and 6.

Subjects will be assigned an enrollment number after signing the informed consent form approved by the UCLA Medical Internal Review Board. Subjects will undergo a physical exam, complete medical history, and blood draw. A standard chem. panel will be performed at the UCLA clinical laboratory. Eligible subjects will be enrolled into the study upon completion of screening evaluations and will be randomized to the strawberry or placebo arm at their baseline visit.

The study will be conducted in healthy free-living subjects (18-55 years). Subjects consume 13 grams standard strawberry powder in the morning and afternoon/evening or placebo powder for 4 weeks. Subjects will be instructed to eat a beige diet (low fiber<10g and low polyphenols <3 servings of polyphenol rich fruit/vegetables per day) during the entire study period. 24 hr urine pelargonidin glucuronide will be measured at weeks 2 (baseline), 6 and 8 for compliance. In addition, pelargondin, ellagic acid, dimethylellagic acid glucuronide and urolithin glucuronide will be measured in plasma and urine to determine strawberry phytochemical bioavailability and intestinal/microbiome metabolic capacity. Participants will meet with the dietitian for assessment of habitual dietary pattern and instructions on maintain on a beige diet. A list of foods with high fiber and phenolic compounds will be provided and subjects are instructed to follow the diet during the entirety of the study.

A standardized freeze-dried strawberry powder and a strawberry placebo powder provided by the California Strawberry Commission will be used. Ten grams of freeze dried powder is equivalent to about 110 g fresh fruit. One serving of fresh strawberry (one cup) is estimated to weigh 144 g and therefore is equivalent to 13 g of freeze dried powder. Subjects will consume two packages of 13 g of strawberry powder per day. The powder can be mixed into beverages and consumed with breakfast and dinner.

Strawberry powder ingredients include Individually Quick Frozen (IQF) strawberries. Placebo powder ingredients include fructose, sucrose, dextrose, tapioca maltodextrin, modified food starch, erythritol, cellulose gum, citric acid (anhydrous), N-C Strawberry Flavor Natual WONF, xanthan gum, malic acid, sugar beet fiber, silicon dioxide, nat. strawberry-type flavor, FD&C Red #40, FD&C Yellow 6, FD&C Blue 2. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04217122
Study type Interventional
Source University of California, Los Angeles
Contact
Status Completed
Phase N/A
Start date September 11, 2018
Completion date December 19, 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Active, not recruiting NCT04552834 - Alterations of the Microbiome During Critical Illness With Short and Long Term Clinical Outcomes
Completed NCT03201068 - Probiotic Supplement and Microbiome, Immune System and Metabolic Syndrome N/A
Recruiting NCT05521295 - Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome
Recruiting NCT05545631 - Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome and Transcriptome
Not yet recruiting NCT05852145 - Oral Changes With Caloric and no Caloric Sweeteners Phase 1/Phase 2
Withdrawn NCT04099446 - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Recruiting NCT05445544 - A Multicenter Cohort Study on Maternal and Infant Microecology and New Targets for Pre-eclampsia Screening in China
Active, not recruiting NCT03213275 - The Premature Gut Microbiome and the Influence on Neonatal Immunity, Brain Development and White Matter Injury
Recruiting NCT05505110 - MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing N/A
Completed NCT04851340 - Investigating the Detection of Bovine and Soy Proteins in Human Milk N/A
Completed NCT06133400 - Mapping the Health Status of the Population of French Polynesia: the MATAEA Project N/A
Withdrawn NCT04114513 - Dietary Fibers Effect on the Gut Microbiota Composition N/A
Not yet recruiting NCT05612620 - Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
Completed NCT04611945 - Westlake Sailing Cohort
Recruiting NCT04260295 - Study of the Correlation of Tumor Tissue Microbiome to the Pathogenesis of Lung Cancer
Completed NCT04155684 - Dysbiosis Impact on Lung Disease in HIV
Completed NCT05510050 - Comparison Study of Manapol and DaltonMax on Immune Function, Microbiome, and Related Variables in Men and Women N/A
Recruiting NCT04865861 - The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Completed NCT03710850 - Modification of Gut Microbiota in the Treatment of Insulin Resistance: a Personalized Approach N/A